Denali Therapeutics reports long-term benefits and safety data for tividenofusp alfa in treating Hunter syndrome (MPS II).
Quiver AI Summary
Denali Therapeutics Inc. announced positive long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) in patients with Hunter syndrome (MPS II), showing sustained reductions in key disease biomarkers and improvements in hearing, cognition, and adaptive behavior after a median follow-up of two years. The treatment was generally well tolerated, with most adverse events being mild or moderate. Denali plans to submit a biologics license application for accelerated approval in early 2025, aiming to launch the therapy for families affected by MPS II by late 2025 or early 2026. The data supporting this application, along with the recent Breakthrough Therapy designation, were presented at the 21st Annual WORLDSymposium conference. Denali is focused on addressing the unmet needs of the Hunter syndrome community by developing treatments that target both cognitive and physical symptoms of the disease.
Potential Positives
- Long-term data indicate that treatment with tividenofusp alfa leads to maintained improvements in key biomarkers related to hearing, cognition, and adaptive behavior in patients with Hunter syndrome.
- The investigational therapeutic tividenofusp alfa has demonstrated long-term safety with a median follow-up of two years, highlighting its general tolerability in study participants.
- Denali Therapeutics plans to submit for accelerated regulatory approval in early 2025, indicating a proactive approach to bringing this treatment to market, with potential availability for patients in late 2025 or early 2026.
- Breakthrough Therapy designation and current research presented at the WORLDSymposium™ conference underscore the unmet needs within the Hunter syndrome community and reinforce Denali’s commitment to addressing these needs through innovative therapies.
Potential Negatives
- Regulatory submission for accelerated approval is planned for early 2025, indicating that the drug is still not yet approved, which may raise concerns about the timeline for bringing the treatment to market.
- While the press release highlights the general tolerability of the treatment, it also mentions that 6.4% of participants experienced serious adverse events, which could raise questions about the treatment's safety profile.
- The mention of significant unmet needs and limitations of existing treatments suggests that the company is entering a competitive space where expectations for efficacy and safety are high, increasing pressure on the success of its product.
FAQ
What is tividenofusp alfa used for?
Tividenofusp alfa is an investigational treatment for Hunter syndrome (MPS II), aiming to address cognitive, behavioral, and physical symptoms.
What are the expected timelines for tividenofusp alfa approval?
Regulatory submission for accelerated approval is planned for early 2025, with a potential U.S. launch in late 2025 or early 2026.
How well was tividenofusp alfa tolerated in studies?
Long-term safety data indicate that tividenofusp alfa was generally well tolerated, with most adverse events being mild or moderate.
What improvements have been observed with tividenofusp alfa treatment?
Participants demonstrated improvements in hearing, cognition, adaptive behavior, and significant reductions in key disease biomarkers.
What is the current status of the Phase 2/3 COMPASS study?
The Phase 2/3 COMPASS study is currently enrolling participants with MPS II across North America, South America, and Europe.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DNLI Insider Trading Activity
$DNLI insiders have traded $DNLI stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $DNLI stock by insiders over the last 6 months:
- DAVID P SCHENKEIN has made 0 purchases and 2 sales selling 59,441 shares for an estimated $1,932,665.
- RYAN J. WATTS (President and CEO) has made 0 purchases and 4 sales selling 79,176 shares for an estimated $1,912,320.
- STEVE E. KROGNES has made 0 purchases and 4 sales selling 65,066 shares for an estimated $1,588,969.
- ALEXANDER O. SCHUTH (COFO and Secretary) has made 0 purchases and 9 sales selling 41,345 shares for an estimated $1,025,984.
- CAROLE HO (Chief Medical Officer) has made 0 purchases and 6 sales selling 39,957 shares for an estimated $911,712.
- VICKI L SATO has made 0 purchases and 6 sales selling 11,280 shares for an estimated $285,985.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DNLI Hedge Fund Activity
We have seen 116 institutional investors add shares of $DNLI stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 7,596,508 shares (+3234.3%) to their portfolio in Q3 2024, for an estimated $221,286,278
- BAILLIE GIFFORD & CO removed 1,031,956 shares (-7.7%) from their portfolio in Q4 2024, for an estimated $21,031,263
- ALLIANCEBERNSTEIN L.P. added 1,028,730 shares (+51.0%) to their portfolio in Q3 2024, for an estimated $29,966,904
- WELLINGTON MANAGEMENT GROUP LLP added 903,683 shares (+9.2%) to their portfolio in Q3 2024, for an estimated $26,324,285
- CAPITAL RESEARCH GLOBAL INVESTORS added 782,581 shares (+11.0%) to their portfolio in Q3 2024, for an estimated $22,796,584
- POINT72 ASSET MANAGEMENT, L.P. removed 719,620 shares (-68.3%) from their portfolio in Q3 2024, for an estimated $20,962,530
- PRICE T ROWE ASSOCIATES INC /MD/ added 614,325 shares (+27.2%) to their portfolio in Q3 2024, for an estimated $17,895,287
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behavior
Long-term safety data with median follow-up of two years, and out to more than four years, demonstrate that tividenofusp alfa was generally well tolerated
Regulatory submission for accelerated approval is planned for early 2025; U.S. launch preparation is ongoing to deliver tividenofusp alfa to families with MPS II in late 2025 or early 2026
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company’s plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLD
Symposium™
conference in San Diego, California.
“Longer-term clinical data add to confidence that normalization of key biomarkers endures over time and that treatment with tividenofusp alfa is associated with continued improvement in hearing, cognition and behavior, which is meaningful to affected individuals and their families,” said Joseph Muenzer, M.D., Ph.D., Director of the Muenzer MPS Center and Professor in Pediatric Genetics at the University of North Carolina at Chapel Hill School of Medicine as well as an investigator in the Phase 1/2 study. “I look forward to new treatment options urgently needed by the Hunter syndrome community that effectively address the full spectrum of the disease.”
“Our primary analysis in 47 participants with MPS II and the additional long-term data in up to more than four years, support the potential of tividenofusp alfa to address neurocognitive, behavioral, and physical effects for all individuals living with MPS II. We are working as fast as possible to enable tividenofusp alfa as a treatment option for individuals living with MPS II and enable access for them and their families,” said Carole Ho, M.D., Chief Medical Officer of Denali. “We expect the progress achieved in our Hunter syndrome program to inform and accelerate additional therapeutics programs in our lysosomal storage disease portfolio, including Sanfilippo syndrome Type A (MPS IIIA).”
The additional Phase 1/2 long-term data demonstrated that treatment with tividenofusp alfa led to substantial and significant reductions to normal and near-normal levels in central nervous system and peripheral biomarkers of disease, including cerebrospinal fluid (CSF) and urine heparan sulfate, and neurofilament light (NfL), a well-established marker of neurodegeneration. Clinical outcomes included normal liver volume after 24 weeks, hearing threshold improvement in all tested frequencies, and skill gains in most participants on measures of adaptive behavior and cognition. Administration of tividenofusp alfa was generally well tolerated in study participants. Most treatment-related adverse events (TEAEs) were mild or moderate, including infusion-related reactions (IRRs), anemia, vomiting, pyrexia, respiratory infections, and rash. Serious TEAEs in three participants (6.4%) were manageable, with resolution or stabilization with continued treatment. One participant discontinued treatment for reasons related to a moderate IRR and other non-treatment-related adverse events.
Denali also supported additional research relating to Hunter syndrome (MPS II) at the WORLD
Symposium™
conference. Research presented by Barbara Burton, M.D., Professor of Pediatrics, Genetics, Genomics and Metabolism at Feinberg School of Medicine in Chicago identified unmet needs including limitations of existing treatments across disease manifestations and the challenges in care associated with diagnosis and continuation of care. Denali researchers also presented research at the conference demonstrating that age-based levels of CSF and urine biomarkers in Hunter syndrome (MPS II) were elevated above biomarker levels at pediatric age-based reference intervals.
About Hunter Syndrome (MPS II)
Hunter syndrome (MPS II) is a rare genetic disease that affects over 2,000 individuals in commercially accessible geographies, primarily males, and leads to physical, cognitive, and behavioral symptoms. Hunter syndrome is caused by mutations in the iduronate-2-sulfatase (IDS) gene, which leads to a deficiency of the IDS enzyme. Symptoms often begin emerging around age two and include physical complications, including organ dysfunction, joint stiffness, hearing loss and impaired growth, and neurocognitive symptoms with impaired development. The disease is characterized by a buildup of glycosaminoglycans (GAGs) in lysosomes — the part of the cell that breaks down materials including GAGs. The current standard of care, enzyme replacement therapy, partially treats physical symptoms but does not cross the blood-brain barrier, and as a result, cognitive and behavioral symptoms experienced by the majority of individuals with Hunter syndrome are not addressed. Therapies that address the range of behavioral, cognitive, and physical manifestations of the disease are recognized as an unmet need for the Hunter syndrome community.
1
About Tividenofusp Alfa and the Phase 2/3 COMPASS Study
Tividenofusp alfa (or DNL310) is composed of the iduronate 2-sulfatase (IDS) enzyme fused to Denali’s proprietary Enzyme TransportVehicle™ (ETV), uniquely designed to deliver IDS into the brain and the body, with the goal of addressing behavioral, cognitive, and physical symptoms of Hunter syndrome (MPS II). The U.S. Food and Drug Administration has granted Fast Track and Breakthrough Therapy designations to tividenofusp alfa for development in the treatment of Hunter syndrome (MPS II). The European Medicines Agency has granted Priority Medicines designation to tividenofusp alfa.
The Phase 2/3 COMPASS study is enrolling participants with MPS II in North America, South America, and Europe to support global approval. Participants are randomized 2:1 to receive either tividenofusp alfa or idursulfase, respectively. Enrollment of the planned 33 participants with neuronopathic MPS II in Cohort A has been completed; Denali has increased the sample size of Cohort A by nine participants, bringing the total to 42 participants. Cohort B continues to enroll participants with non-neuronopathic MPS II. More information about the COMPASS study can be found
here
.
Tividenofusp alfa is an investigational therapeutic candidate and has not been approved for use by any Health Authority.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit
www.denalitherapeutics.com
.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding plans, timelines, and expectations related to Denali's TransportVehicle™ (TV) platform and its therapeutic and commercial potential; plans, timelines, and expectations relating to DNL310, including enrollment in the ongoing global Phase 2/3 COMPASS study, the likelihood of global approvals, the timing of planned regulatory filings, and the timing, likelihood, and scope of regulatory approvals and commercial launch; plans, timelines, and expectations related to DNL126; and statements made by Dr. Muenzer and Denali’s Chief Medical Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Denali’s dependence on successful development of its BBB platform technology and TV-enabled product candidates; Denali’s ability to initiate and enroll patients in its current and future clinical trials; Denali’s ability to conduct or complete clinical trials on expected timelines; Denali’s reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that product candidates may not receive regulatory approval necessary to be commercialized; developments relating to Denali’s competitors and its industry, including competing product candidates and therapies; Denali’s ability to obtain, maintain, or protect intellectual property rights; and other risks and uncertainties. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. No Denali product candidates have been approved by any health authority for any use. Information regarding additional risks and uncertainties may be found in Denali’s Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali’s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.
References
Muenzer, J.,
et al.
Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
Mol Genet Metab
. 2024 Aug;142(4):108535
Investor Contact
Laura Hansen, Ph.D.
Vice President, Investor Relations
(650) 452-2747
hansen@dnli.com
Media Contact
Rich Allan
FGS Global
(503) 851-0807
rich.allan@fgsglobal.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
